Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL from Follicular NHL are eligible). 
Prior transplant with stem cell infusion 90 days or active graft-versus-host treatment within 8 weeks of Day 1. 
Prior therapy with SYK inhibitors. 
Chronic treatment with strong CYP3A4 inhibitor/ inducer, acid reducing agent, Proton pump inhibitors 
Known lymphomatous involvement of the CNS. 
Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy). 
Prior monoclonal antibody, radioimmunoconjugate, antibody drug conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any test agent within 3 weeks or for alemtuzumab 8 weeks of Day 1. 
For CTCL: (TSEBT) within 12 weeks, or initiation of topical steroid, nitrogen mustard, or topical retinoid within 2 weeks. (Stable topical ≥ 4 weeks prior to Day 1 allowed). 
Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be HBsAg- or undetectable DNA 
Active infection requiring systemic treatment, 
Significant GI disease, previous major gastric/bowel surgery, difficulty swallowing or malabsorption syndrome. 
Major surgery within 4 weeks 
Previous malignancies within 2 yrs. unless relapse risk is small (< 5%). 
Current use of systemic steroids >20 mg QD prednisone (or equivalent) 
Breastfeeding or pregnant (intention to become) females or participation in other clinical trials       
    

NCT01994382_exc_T1
Condition
Richter's syndrome
NCT01994382_exc_T2
Condition
Burkitt's lymphoma
NCT01994382_exc_T3
Condition
Burkitt-like Lymphoma
NCT01994382_exc_T4
Condition
DLBCL
NCT01994382_exc_T5
Condition
Follicular NHL
NCT01994382_exc_T6
Procedure
transplant
NCT01994382_exc_T7
Procedure
stem cell infusion
NCT01994382_exc_T8
Temporal
90 days of Day 1
NCT01994382_exc_T9
Temporal
active
NCT01994382_exc_T10
Procedure
graft-versus-host treatment
NCT01994382_exc_T11
Temporal
within 8 weeks of Day 1
NCT01994382_exc_T12
Drug
SYK inhibitors
NCT01994382_exc_T13
Procedure
therapy
NCT01994382_exc_T14
Temporal
Prior
NCT01994382_exc_T15
Temporal
Prior
NCT01994382_exc_T16
Drug
strong CYP3A4 inhibitor
NCT01994382_exc_T17
Drug
strong CYP3A4 inducer
NCT01994382_exc_T18
Drug
acid reducing agent
NCT01994382_exc_T19
Drug
Proton pump inhibitors
NCT01994382_exc_T20
Condition
lymphomatous involvement of the CNS
NCT01994382_exc_T22
Measurement
NCI CTCAE v4.0
NCT01994382_exc_T23
Value
≥ Grade 2
NCT01994382_exc_T24
Condition
drug-related toxicity
NCT01994382_exc_T25
Temporal
previous
NCT01994382_exc_T26
Condition
alopecia
NCT01994382_exc_T27
Negation
except
NCT01994382_exc_T28
Condition
erectile impotence
NCT01994382_exc_T29
Condition
hot flashes
NCT01994382_exc_T30
Condition
libido
NCT01994382_exc_T31
Condition
neuropathy
NCT01994382_exc_T32
Scope
alopecia, erectile impotence, hot flashes, libido, neuropathy
NCT01994382_exc_T33
Drug
monoclonal antibody
NCT01994382_exc_T34
Drug
radioimmunoconjugate
NCT01994382_exc_T35
Drug
antibody drug conjugate
NCT01994382_exc_T36
Procedure
phototherapy
NCT01994382_exc_T37
Procedure
radiotherapy
NCT01994382_exc_T38
Procedure
chemotherapy
NCT01994382_exc_T39
Procedure
immunotherapy
NCT01994382_exc_T40
Procedure
immunosuppressive therapy
NCT01994382_exc_T41
Temporal
within 3 weeks of Day 1
NCT01994382_exc_T42
Drug
alemtuzumab
NCT01994382_exc_T43
Temporal
8 weeks of Day 1
NCT01994382_exc_T44
Scope
monoclonal antibody, radioimmunoconjugate, antibody drug conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy
NCT01994382_exc_T45
Scope
within 3 weeks or for alemtuzumab 8 weeks of Day 1
NCT01994382_exc_T46
Reference_point
Day 1
NCT01994382_exc_T47
Condition
CTCL
NCT01994382_exc_T48
Procedure
TSEBT
NCT01994382_exc_T49
Temporal
within 12 weeks
NCT01994382_exc_T50
Drug
topical steroid
NCT01994382_exc_T51
Observation
initiation
NCT01994382_exc_T52
Drug
nitrogen mustard
NCT01994382_exc_T53
Drug
topical retinoid
NCT01994382_exc_T54
Temporal
within 2 weeks
NCT01994382_exc_T55
Scope
topical steroid, nitrogen mustard, or topical retinoid
NCT01994382_exc_T56
Temporal
≥ 4 weeks prior to Day 1
NCT01994382_exc_T57
Reference_point
Day 1
NCT01994382_exc_T59
Condition
infection for HIV
NCT01994382_exc_T60
Condition
Hep B infection for
NCT01994382_exc_T61
Condition
Hep C infection for
NCT01994382_exc_T62
Condition
HCV ab+
NCT01994382_exc_T63
Qualifier
PCR-
NCT01994382_exc_T64
Condition
HBV ab+
NCT01994382_exc_T65
Qualifier
HBsAg-
NCT01994382_exc_T66
Condition
undetectable DNA
NCT01994382_exc_T67
Scope
infection for HIV/Hep B or C
NCT01994382_exc_T68
Condition
infection
NCT01994382_exc_T69
Procedure
systemic treatment
NCT01994382_exc_T70
Qualifier
requiring systemic treatment
NCT01994382_exc_T71
Condition
GI disease
NCT01994382_exc_T72
Qualifier
Significant
NCT01994382_exc_T74
Procedure
bowel surgery
NCT01994382_exc_T75
Procedure
gastric surgery
NCT01994382_exc_T76
Qualifier
major
NCT01994382_exc_T78
Condition
difficulty swallowing
NCT01994382_exc_T79
Condition
malabsorption syndrome
NCT01994382_exc_T80
Scope
gastric/bowel surgery
NCT01994382_exc_T81
Procedure
surgery
NCT01994382_exc_T82
Qualifier
Major
NCT01994382_exc_T85
Temporal
within 4 weeks
NCT01994382_exc_T86
Condition
malignancies
NCT01994382_exc_T87
Temporal
within 2 yrs.
NCT01994382_exc_T91
Drug
systemic steroids
NCT01994382_exc_T92
Multiplier
>20 mg QD
NCT01994382_exc_T93
Drug
prednisone
NCT01994382_exc_T94
Observation
Breastfeeding
NCT01994382_exc_T95
Condition
pregnant
NCT01994382_exc_T96
Person
females